Martin Smoragiewicz
Overview
Explore the profile of Martin Smoragiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1053
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Winquist E, Hotte S, Chi K, Sridhar S, Ellard S, Ong M, et al.
Clin Cancer Res
. 2024 Nov;
31(1):45-55.
PMID: 39513948
Purpose: PD-L1 is overexpressed by dendritic cells in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on androgen receptor pathway inhibitors. We tested whether checkpoint blockade could enhance antitumor activity...
2.
Baran E, Lee M, Aviv S, Weiss J, Pettengell C, Karam I, et al.
JAMA Otolaryngol Head Neck Surg
. 2024 May;
150(12):1051-1057.
PMID: 38754135
Importance: Accurate, timely, and cost-effective methods for staging oropharyngeal cancers are crucial for patient prognosis and treatment decisions, but staging documentation is often inaccurate or incomplete. With the emergence of...
3.
Mutsaers A, Akingbade A, Louie A, Said B, Zhang L, Poon I, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473213
Introduction: Stereotactic body radiotherapy (SBRT) is increasingly used to treat disease in the oligometastatic (OM) setting due to mounting evidence demonstrating its efficacy and safety. Given the low population representation...
4.
Wang X, Waldman L, Silberman Y, Wang M, Tackey C, Hanna L, et al.
Clin Genitourin Cancer
. 2024 Mar;
22(3):102052.
PMID: 38461085
Background: An estimated 20% to 30% of men with advanced prostate cancer carry a mutation in DNA damage repair genes, of which half are estimated to be germline. Eligibility criteria...
5.
Khalil C, Khoury M, Higgins K, Enepekides D, Karam I, Husain Z, et al.
Head Neck
. 2024 Feb;
46(8):1965-1974.
PMID: 38344842
Background: Lymph node metastases are associated with poor prognosis in oral cavity squamous cell carcinoma (OCSCC). In other cancers, clinical guidelines on the number of lymph nodes removed during primary...
6.
Sampieri G, Li H, Ataalla P, Merriman K, Noel C, Hallet J, et al.
Ann Surg Oncol
. 2023 Dec;
31(3):1495-1496.
PMID: 38133860
No abstract available.
7.
Sampieri G, Li H, Ataalla P, Merriman K, Noel C, Hallet J, et al.
Ann Surg Oncol
. 2023 Nov;
31(2):1148-1170.
PMID: 37996640
Importance: Collecting patient-reported outcomes (PROs) in routine cancer care improves patient-clinician communication, decision making, and overall patient satisfaction. Recommendations exist regarding standardized ways to collect, store, and interpret PRO data....
8.
Du Y, Fu R, Levinsky J, Kamalraj P, Chan K, Parmar A, et al.
Curr Oncol
. 2023 Oct;
30(10):8928-8935.
PMID: 37887545
Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase...
9.
10.
Khan M, Parshad S, Naimi M, Sidhu A, Lyons F, Hardisty M, et al.
Clin Genitourin Cancer
. 2023 Feb;
21(4):e228-e235.e1.
PMID: 36849325
Introduction: Osteosarcopenia is the progressive loss of musculoskeletal structure and functionality, contributing to disability and mortality. Despite complex interactions between bone and muscle, osteosarcopenia prevention and treatment in men with...